Navigation Links
Neogen comments on SenesTech
Date:7/24/2014

LANSING, Mich., July 24, 2014 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) advised market analysts today that future forecasts of its potential revenue from new rodenticide research are premature. In its regular quarterly conference call to investors and analysts on July 22, 2014, Neogen's CEO commented about several new developments when questioned by analysts regarding this research.

"It was my intent Tuesday at our conference call to answer questions about the potential of a new type of rodenticide, but certainly not to give any indication of size of that market," said James Herbert, Neogen's chief executive officer and chairman. "When asked about market studies, I declined any market projections since it is our intention to market this rodenticide in combination with our other current formulas. I also indicated that we hoped to submit application for approval to the U. S. Environmental Protection Agency sometime this summer, and though optimistic of eventual approval, could not forecast timing."

Neogen issued a press release on June 16, 2014, that it had licensed patents to a rodenticide aimed at controlling rodents through fertility control. The company indicated it was currently doing more beta site testing in field situations with natural rodent populations and was still awaiting those results before making any further investments.   

The company made these comments because of market reactions to published research on Wednesday that drove up both the price of the stock and volume. 

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division is a leader in the development of animal genomics, along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.

CONTACT:
Steven J. Quinlan, Vice President & CFO
517/372-9200 


'/>"/>
SOURCE Neogen Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Corporation Announces 2nd Quarter Results Conference Call
2. Neogen Reports Second Quarter Results
3. Neogen Launches Fully Quantitative Lateral Flow Test for DON
4. Neogen launches the fastest molecular pathogen test
5. Neogen acquires Igenity from Merial
6. Neogen Corporation Announces Year-End Results Conference Call
7. Neogen reports year end results
8. Neogen Corporation Announces 1st Quarter Results Conference Call
9. Neogen reports 30% increase in quarterly net income
10. Neogen Corporation Announces 3rd Quarter Results Conference Call
11. Neogen launches rapid tests for ractopamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):